Akari Therapeutics
AKTX
8 hedge funds and large institutions have $536K invested in Akari Therapeutics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.
10% more capital invested
Capital invested by funds: $488K → $536K (+$47.8K)
0% more funds holding
Funds holding: 8 → 8 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$116K |
| 2 |
Renaissance Technologies
New York
|
+$3.48K |
| 3 |
TC
Truvestments Capital
Sarasota,
Florida
|
+$139 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$48.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$43.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OFW
1
Omnia Family Wealth
Aventura,
Florida
| $259K | – | – | – |
|
|
2
Citadel Advisors
Miami,
Florida
| $99.1K | +$116K | +832 | New |
|
3
Cerity Partners
New York
| $69.7K | – | – | – |
|
|
CAM
4
Cresset Asset Management
Chicago,
Illinois
| $54.3K | – | – | – |
|
|
5
Renaissance Technologies
New York
| $53.3K | +$3.48K | +25 | +6% |
|
6
Bank of America
Charlotte,
North Carolina
| $442 | – | – | – |
|
7
Osaic Holdings
Scottsdale,
Arizona
| $295 | – | – | – |
|
|
TC
8
Truvestments Capital
Sarasota,
Florida
| $148 | +$139 | +1 | New |
|
9
Morgan Stanley
New York
| $24 | – | – | – |
|
|
CPG
10
Cornerstone Planning Group
Fairfield,
New Jersey
| $13 | – | – | – |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$48.1K | -431 | Closed |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$43.1K | -399 | Closed |
|
AKTX Hedge Fund Activity: Q3 2024 in Review
8 of the 6,967 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q3 2024, worth a combined $536K — up 9.8% from $488K a quarter earlier.
Fund positioning in AKTX was balanced in Q3 2024: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $116K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $48.1K sold.
- 8 institutional investors held Akari Therapeutics (AKTX) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $536K of Akari Therapeutics stock for Q3 2024, up 9.8% quarter-over-quarter.
- 2 funds opened new Akari Therapeutics positions in Q3 2024 and 2 closed out, a net change of 0 holders.
- The largest Akari Therapeutics buyer in Q3 2024 was Citadel Advisors, an estimated $116K added.
- The largest Akari Therapeutics seller in Q3 2024 was Susquehanna International Group, an estimated $48.1K sold.
Based on aggregated 13F filings for Q3 2024.